Stock listing

Frankfurt:8AP Agios Pharmaceuticals, Inc. Aktie

German listing (Frankfurt) of Agios Pharmaceuticals, Inc. · home listing NASDAQ:AGIO

Follow Agios Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · FWB:8AP

€32.80 EUR +0.40 (+1.2%)

Close on Oct 30, 2026

Day range
€32.80 – €32.80 EUROct 30, 2026
Market cap
€1.96B EURAt the close on Oct 30, 2026 · price × 59.70M shares outstanding
Agios Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:AGIO · Home$30.55 USD-6.68 (-17.9%)3,094,260$31.43$33.00$29.80$37.23Close on Oct 30, 2026
LSE:0HB0$37.56 USD+0.38 (+1.0%)232$37.35$37.56$36.50$37.18Close on Oct 27, 2026
Frankfurt:8AP€32.80 EUR+0.40 (+1.2%)—€32.80€32.80€32.80€32.40Close on Oct 30, 2026
Ticker
Frankfurt:8AP
Asset type
Stock
Exchange
Frankfurt
Currency
EUR

What changed lately

Calls

Upcoming

  • Agios Pharmaceuticals (NASDAQ:AGIO) Q3 2026 Earnings Call

    Thu, Nov 05, 2026 · 8:00 AM ET

    Register

Replays

  • Agios Pharmaceuticals (NASDAQ:AGIO) Q2 2026 Earnings Call

    Thu, Jul 30, 2026 · 8:00 AM ET

    Watch Transcript

  • Agios Pharmaceuticals (NASDAQ:AGIO) Q1 2026 Earnings Call

    Wed, Apr 29, 2026 · 8:00 AM ET

    Watch Transcript

  • Agios Pharmaceuticals (NASDAQ:AGIO) Q4 2025 Earnings Call

    Thu, Feb 12, 2026 · 8:00 AM ET

    Watch Transcript

Latest news

Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA

Oct 30, 2026

Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8: 00 a.m. ET

Oct 8, 2026

Agios Reports Second Quarter 2026 Financial Results and Provides Business Update

Jul 30, 2026

Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease

Jul 21, 2026

U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease

Jul 7, 2026

Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8: 00 a.m. ET

Jun 29, 2026

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

Jun 13, 2026

Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib

Jun 1, 2026

Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes

May 29, 2026

Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia

May 22, 2026

All Agios Pharmaceuticals, Inc. news

Decks

Agios Pharmaceuticals, Inc. on 6ix

News releases
24 in the last 12 months · 218 in all · newest Oct 30, 2026 · oldest 2019
Calls
26 calls with a replay · 26 with a transcript · latest Jul 30, 2026
Decks
37 decks · latest Jul 30, 2026

Where Agios Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:AGIO · Home listingNASDAQUnited StatesUSD
Lang & Schwarz:A1W2RMLang & SchwarzGermanyEUR
LS Exchange:A1W2RMLS ExchangeGermanyEUR
gettex:8APgettexGermanyEUR
LSE:0HB0LSEUnited KingdomUSD
BMV:AGIOBMVMexicoMXN
Tradegate:8APTradegateGermanyEUR
BOATS:AGIOBOATSUnited StatesUSD
BIVA:AGIOBIVAMexicoMXN
BX Swiss:8APBX SwissSwitzerlandCHF
Dusseldorf:8APDusseldorfGermanyEUR
Frankfurt:8AP · This pageFrankfurtGermanyEUR
Munich:8APMunichGermanyEUR
Stuttgart:8APStuttgartGermanyEUR

Log in to ask 6ix AI your own questions about Agios Pharmaceuticals, Inc.